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Four clinical trials, the Royal Marsden, the Italian,
the American National Surgical Adjuvant Breast and
Bowel Project (NSABP) and the United Kingdom (UK)
IBIS (International Breast Intervention Study) trials,
have been reported evaluating tamoxifen used in healthy
women to prevent breast cancer [1–4]. After 10 years of
follow-up, the Marsden trial shows no signiﬁcant risk
reduction for breast cancer. The Italian trial was also
initially negative, but now shows a small risk reduction.
The UK IBIS trial showed a risk reduction, but this was
not signiﬁcant for invasive breast cancer. The largest
study, the NSABP trial, reported a very signiﬁcant risk
reduction for breast cancer.
The entry criteria for each of these trials were based
on various risk factors. The Royal Marsden trial was a
younger population-based subject group with a strong
family history. The IBIS trial was similar to the Mars-
den trial, but included patients with a lower risk as-
sessment. The NSABP trial was based on the Gail model
and the Italian trial had no special risk criteria, but re-
quired all of the participants to have had a hyster-
ectomy. These diﬀerences in entry criteria probably
account for much of the variation in outcomes.
A meta-analysis of these trials has shown that tamox-
ifen given for 5 years will reduce the risk of breast cancer
by approximately 40% [5]. However, there is signiﬁcant
toxicity with an increased risk of endometrial polyps and
cancer, venous thrombo-embolism, vasomotor symp-
toms and cataracts. Clinical beneﬁt from this risk reduc-
tion for breast cancer has not been clearly established.
Another selective oestrogen receptor modulator
(SERM), raloxifene, has been used in an osteoporosis
clinical trial in post-menopausal women and been shown
to reduce the risk of fractures [6], myocardial infarcts [7]
and breast cancer [8]. Unlike tamoxifen, raloxifene is not
oestrogenic on the endometrium, due to an impeded
agonist eﬀect caused by a side-chain on the molecule [9]
and therefore does not cause endometrial cancer. The
NSABP P2 trial is now comparing raloxifene with ta-
moxifen for risk reduction eﬀects. Due to its impeded
oestrogenic activity, it is likely that raloxifenewill bemore
active than tamoxifen for the prevention of breast cancer.
Other SERMs, such as lasofoxifene, are also being
evaluated.
The aromatase inhibitors, anastrozole, letrozole and
exemestane have been shown to reduce the risk of con-
tralateral breast cancer better than tamoxifen in the
adjuvant breast cancer trials [10]. The IBIS II trial has
started randomising healthy women with a family his-
tory of breast cancer to anastrozole or placebo, and
other aromatase inhibitors are likely to be evaluated in
primary prevention trials in the near future.
No trials at this time are directly comparing an ar-
omatase inhibitor with a SERM. The relative merits of
these two types of intervention for the chemoprevention
of breast cancer needs to be addressed.
To date, the results of the adjuvant and prevention
trials show that endocrine prevention of breast cancer is
possible, but it will be necessary to use more active, and
less toxic, agents than tamoxifen.
For future trials, an evaluation of the risk factors
which predispose to the oestrogenic promotion of breast
cancer, rather than using the Gail model, may allow the
identiﬁcation of those women likely to gain beneﬁt from
anti-oestrogenic intervention using SERMs or ar-
omatase inhibitors.
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